Hjertemagnyl (Acetylsalicylic Acid)

Hjertemagnyl is prescribed to lower the risk of clot‑related cardiovascular events. It is commonly used in patients with established heart or vascular disease and in those at high risk for such conditions.

• Prevention of first or recurrent myocardial infarction
• Reduction of risk for ischemic stroke in patients with atherosclerotic disease
• Long‑term antiplatelet therapy after coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI)
• Adjunctive treatment in peripheral arterial disease to prevent thrombotic complications
• Secondary prevention in patients with a history of transient ischemic attack (TIA)

• Acetylsalicylic acid irreversibly inhibits the cyclooxygenase‑1 (COX‑1) enzyme in platelets, which blocks the conversion of arachidonic acid to thromboxane A2, a potent promoter of platelet aggregation and vasoconstriction. By reducing thromboxane A2 production, platelet activation is suppressed, leading to a prolonged antiplatelet effect that helps prevent arterial thrombus formation.

Adverse reactions to Hjertemagnyl can vary in frequency and severity.

Common

• Gastrointestinal discomfort, such as dyspepsia or abdominal pain
• Minor bruising or prolonged bleeding from cuts
• Nausea or mild vomiting
• Headache or dizziness
• Rash or mild skin irritation

Serious

• Gastrointestinal ulceration or bleeding, including melena
• Severe hemorrhage, such as intracranial or intra‑ocular bleeding
• Allergic reactions like angioedema or anaphylaxis
• Hepatic dysfunction or elevated liver enzymes
• Renal impairment or acute kidney injury

Before starting Hjertemagnyl, certain health considerations should be reviewed to minimize risk.

• History of peptic ulcer disease or gastrointestinal bleeding
• Known hypersensitivity to aspirin or other NSAIDs
• Active bleeding disorders or recent major surgery
• Severe liver or kidney disease
• Pregnancy, especially in the third trimester, unless advised by a physician
• Concomitant use of other antithrombotic agents
• Children or adolescents with viral infections due to risk of Reye syndrome

Hjertemagnyl can interact with several medications, affecting either its efficacy or safety profile.

Avoid

• Other antiplatelet or anticoagulant drugs (e.g., clopidogrel, warfarin, direct oral anticoagulants) due to increased bleeding risk
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may exacerbate gastrointestinal toxicity
• Selective serotonin reuptake inhibitors (SSRIs) which can potentiate bleeding

Use with caution

• Corticosteroids, which may increase ulcer risk
• ACE inhibitors or ARBs, as aspirin can reduce their renal protective effects
• Diuretics, especially in patients with compromised kidney function
• Methotrexate, where aspirin may raise serum levels
• Certain antihypertensive agents, as aspirin may blunt blood pressure control